Evidence map›Paper›PMID 23400279›Full record

Trial reportJAMA internal medicine2013

Comparing 3 techniques for eliciting patient values for decision making about prostate-specific antigen screening: a randomized controlled trial.

Michael Patrick Pignone, Kirsten Howard, Alison Tytell Brenner, Trisha Melinda Crutchfield, Sarah Tropman Hawley, Carmen Lynn Lewis, Stacey Lynn Sheridan

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in JAMA internal medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04083859 (A Pragmatic Randomized-Controlled Trial of a Digital Outreach Intervention for Lung Cancer Screening), which is not on this map. Cited by 22 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04083859 nacompletednot on this mapstarted 2022, after this paper: background citation

A Pragmatic Randomized-Controlled Trial of a Digital Outreach Intervention for Lung Cancer Screening: mPATH-Lung (Mobile Patient Technology for Health-Lung)

TypeinterventionalSponsorWake Forest University Health SciencesRan2022 to 2024Enrolled26,998ConditionsLung CancerArmsmPATH-Lung, Lung health video
3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Decision aids for people facing health treatment or screening decisions.The Cochrane database of systematic reviews · 2024
    Pooled it
  2. Pooled it
  3. Clarifying Values: An Updated and Expanded Systematic Review and Meta-Analysis.Medical decision making : an international journal of the Society for Medical Decision Making · 2021
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Decision aids for people facing health treatment or screening decisions.The Cochrane database of systematic reviews · 2017
    Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Harms and Benefits of Cancer Screening.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2021
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. A descriptive review on methods to prioritize outcomes in a health care context.Health expectations : an international journal of public participation in health care and health policy · 2015
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Michael Patrick PignoneCecil G. Sheps Center for Health Services Research, Universityof North Carolina at Chapel Hill, 725 Martin LutherKing Jr Blvd, Chapel Hill, NC 27599, USA. pignone@med.unc.edu
Kirsten Howard
Alison Tytell Brenner
Trisha Melinda Crutchfield
Sarah Tropman Hawley
Carmen Lynn Lewis
Stacey Lynn Sheridan

Funding

Improving Cancer-Related Patient Decision MakingK05CA129166 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PIGNONE, MICHAEL P · 2008 to 2012
$765k
NCI NIH HHS K05 CA129166
6 · The paper itself

Abstract

importanceTo make good decisions about prostate-specific antigen (PSA) screening, men must consider how they value the different potential outcomes.

objectiveTo determine the effects of different methods of helping men consider such values. DESIGN AND

settingRandomized trial from October 12 to 27, 2011, in the general community.

participantsA total of 911 men aged 50 to 70 years from the United States and Australia who had average risk. Participants were drawn from online panels from a survey research firm in each country and were randomized by the survey firm to 1 of 3 values clarification methods: a balance sheet (n = 302), a rating and ranking task (n = 307), or a discrete choice experiment (n = 302).

interventionParticipants underwent a values clarification task and then chose the most important attribute.

main outcome measuresThe main outcome was the difference among groups in the most important attribute. Secondary outcomes were differences in unlabeled test preference and intent to undergo screening with PSA.

resultsThe mean age was 59.8 years; most participants were white and more than one-third had graduated from college. More than 40% reported a PSA test within 12 months. The participants who received the rating and ranking task were more likely to report reducing the chance of death from prostate cancer as being most important (54.4%) compared with those who received the balance sheet (35.1%) or the discrete choice experiment (32.5%) (P < .001). Those receiving the balance sheet were more likely (43.7%) to prefer the unlabeled PSA-like option (as opposed to the "no screening"-like option) compared with those who received rating and ranking (34.2%) or the discrete choice experiment (20.2%). However, the proportion who intended to undergo PSA testing was high and did not differ between groups (balance sheet, 77.1%; rating and ranking, 76.8%; and discrete choice experiment, 73.5%; P = .73). CONCLUSIONS AND RELEVANCE: Different values clarification methods produce different patterns of attribute importance and different preferences for screening when presented with an unlabeled choice. Further studies with more distal outcome measures are needed to determine the best method of values clarification, if any, for decisions such as whether to undergo screening with PSA.

Indexed as

Patient NavigationPatient ParticipationProstatic NeoplasmsAgedAustraliaChoice BehaviorData Interpretation, StatisticalDecision MakingEducational StatusEthnicityHumansMaleMass ScreeningMiddle AgedOutcome Assessment, Health CarePreventive Health ServicesProstate-Specific Antigen

Identifiers

PMID23400279
PMCPMC3974265

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.